Inhibrx Inc outlook after merger closing, shares remain a biotech niche story
25.06.2026 - 22:27:16 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 22:26.
Inhibrx Inc (US45720L1070) has traded quietly since its oncology assets were acquired by Sanofi in a deal that closed in May 2024. The remaining Inhibrx vehicle offers investors exposure to a narrower rare-disease pipeline while its shares continue to change hands on NASDAQ.
What the Sanofi deal changed
In February 2024 Sanofi completed the acquisition of the pre-merger Inhibrx Inc, paying 30 dollars in cash per share plus one contingent value right tied to an oncology asset milestone, as detailed in the company's merger communication on its investor relations site. The transaction description on the Inhibrx investor relations page explains that Sanofi gained control of the oncology pipeline while certain non-oncology assets and cash were spun into the current Inhibrx structure.
Under the merger terms Sanofi integrated key antibody-drug conjugate and immuno-oncology candidates into its own pipeline, seeking to strengthen its oncology footprint alongside peers such as AstraZeneca and Roche. The newly configured Inhibrx entity retained programs outside oncology, most notably INBRX-101 for alpha-1 antitrypsin deficiency, positioning it as a focused rare-disease developer in the U.S. biotech universe.
Current pipeline and development focus
Following the closing of the acquisition and spin-out, Inhibrx describes itself as a clinical-stage biotech concentrated on rare and serious diseases, with INBRX-101 highlighted as a lead program in respiratory medicine. The company's pipeline overview on its website lists INBRX-101 as a recombinant human alpha-1 antitrypsin designed for less frequent dosing, which is being tested in patients with alpha-1 antitrypsin deficiency. The pipeline page on Inhibrx's corporate site sets out additional earlier-stage candidates, but INBRX-101 remains the most advanced asset for the post-merger company.
Alpha-1 antitrypsin deficiency is a rare genetic condition associated with lung and liver disease, where existing therapies typically require frequent intravenous infusions, and several listed peers such as Arrowhead Pharmaceuticals and Vertex Pharmaceuticals are targeting the same indication with different modalities. Inhibrx is aiming to differentiate INBRX-101 by reducing infusion frequency and improving overall patient convenience, a positioning that, if supported by clinical data, could make the asset commercially relevant within the U.S. and European orphan-drug landscape.
All news and analysis on the Inhibrx Inc shares
Follow the Inhibrx Inc stock story from the Sanofi deal to the current rare-disease focus, including any future clinical readouts and capital moves.
The product behind the stock
INBRX-101 is Inhibrx's lead clinical program, a modified recombinant human alpha-1 antitrypsin intended for patients with alpha-1 antitrypsin deficiency. The company highlights its potential for less frequent dosing than current augmentation therapies, positioning it as a possible convenience upgrade for suitable patients.
Where the stock trades today
At the time of writing Inhibrx Inc shares continue to trade on NASDAQ in U.S. dollars as a small-cap biotech vehicle linked to the spin-out structure from the 2024 Sanofi transaction, without a recent major price-moving announcement in the public domain.
Inhibrx Inc at a glance
- Company: Inhibrx Inc
- ISIN: US45720L1070
- WKN: A2PP9B
- Ticker: INBX
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 20:20): not verifiably quoted in latest public snapshot
- Market cap: not reliably stated in latest public snapshot
- Sector / industry: Health Care - Biotechnology
- Index membership: not a member of a major headline index such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
